“…Recent advances have expanded both the number of recognized inherited metabolic diseases (IMDs) and the understanding of their mechanisms 1 providing opportunities for therapeutic intervention. The financial success of some rare disease drugs, 2 along with legislation encouraging the development of products for orphan diseases, 3 has led to increasing interest from the pharmaceutical industry and more drugs entering into clinical trials.…”